Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial
Recruiting now · Phase 4
Conditions studied: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
In brief
This study aims to determine whether the recurrence rate of high-risk acute myeloid leukemia CR1 patients who received allogeneic hematopoietic stem cell transplantation with the Ruxolitinib, Decitabine combined with Bu/Cy or BuF intensive pretreatment regimen is reduced compared with the traditional Bu/Cy or BuFpretreatment regimen.
Key facts
- Study ID
- NCT07101588
- Run by
- Chinese PLA General Hospital
- People needed
- 200
- Starts
- 2025-01-01
- Expected to finish
- 2028-12-30
- Last updated by the study team
- 2026-03-20
Who can join
Age: 14 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- 1) Acute myeloid leukemia with indications for allogeneic hematopoietic stem cell transplantation, CR1 2) Have HLA-matched sibling donors or haploidentical donors or ≥8/10 HLA-matched unrelated donors 3) The patients' ages range from 12 to 64 years old 4) Liver function: ALT and AST≤2.5 times the upper limit of normal values, bilirubin ≤2 times the upper limit of normal values 5) Renal function: Creatinine ≤ the upper limit of the normal value 6) There are no uncontrollable infections or serious mental and psychological disorders 7) Sign the informed consent form.
You may not qualify if…
- 1. Patients with acute promyelocytic leukemia (M3) 2. One of the donor and recipient is pregnant 3. Suffering from mental illness or other conditions that prevent one from following the plan.
Where it is running
- Chinese PLA General Hospital — Beijing, Beijing Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.